I just went ahead and had ai analyze the different backbone Moa in esmo vs clover. and the potential different synergy w leron.If anyone is interested
Tas 102 I think is superior here
"
To understand why the CLOVER trial design (TAS-102 + Leronlimab) creates a far more devastating biological trap than the ESMO Basket trial (FOLFOX/FOLFOXIR + Leronlimab), we have to look directly at the sub-cellular level—specifically, how these chemotherapies alter the kinetics of the cell cycle and how leronlimab systematically cuts off their survival routes.
When you change the chemotherapy background, you fundamentally alter the type of cell-cycle crisis you are creating. Here is the deep-dive comparison of how these two environments force the cell cycle into completely different corners.
## ???? The Cell-Cycle Mechanics: How They Break the Engine
To visualize the difference, we must trace how a tumor cell moves through its replication cycle ($G_1 \rightarrow S \rightarrow G_2 \rightarrow M$) and where these drugs slam on the brakes.
[ THE SOLID TUMOR CELL CYCLE REPLICATION LOOP ]
G1 Phase (Growth & Preparation)
│
▼
S Phase (DNA Synthesis / Replication)
├──> FOLFOX / FOLFOXIR: Causes variable breaks & strand adducts.
│ (Cell can try to patch this during active replication)
▼
G2 Phase (Proofreading & Damage Check) ──┐
│ │
▼ ▼
M Phase (Mitosis / Division) [ THE CLOVER CELL-CYCLE TRAP ]
TAS-102 forces a hard G2/M Boundary Arrest.
│
▼
[ LERONLIMAB INTERCEPTION ]
Unplugs AKT/mTOR cascade.
Strips Homologous Recombination (RAD51).
│
▼
REPLICATION FORK SHATTERING
(Immediate Mitotic Catastrophe)
## 1. The ESMO Basket Mix (FOLFOX / FOLFOXIR): Disorganized S-Phase Drifting
The components of FOLFOX and FOLFOXIR target the cell cycle while it is actively copying its blueprint during the S phase (Synthesis):
* The Mechanism: Oxaliplatin creates physical bonds across DNA strands (platinum adducts), while Irinotecan binds to Topoisomerase I, an enzyme that unwinds DNA so it can be read.
* The Cell-Cycle Flaw: These drugs damage the DNA while it is actively replicating. Because the S phase is highly dynamic, the tumor cell doesn't stop immediately. It slows down and activates various complex, alternative DNA-patching mechanisms—like Nucleotide Excision Repair (NER) or Base Excision Repair (BER).
* The Structural Leak: Because the cell-cycle arrest is spread out across the S phase, cells drift through the checkpoint at different velocities. In a heavily pre-treated patient whose cells have already evolved anti-platinum defenses, many cells successfully patch these adducts and slide past the checkpoint into normal division, bypassing the therapeutic effect.
## 2. The CLOVER Design (TAS-102): The Hard G2/M Boundary Wall
The combination protocol standardized in the CLOVER trial drops the S-phase approach entirely and relies on Trifluridine (TAS-102) to execute a synchronized cell-cycle freeze:
* The Mechanism: Trifluridine mimics a standard DNA building block (thymidine). As the cell replicates during the S phase, it mistakenly grabs the trifluridine and stitches it directly into its new DNA strands. The cell finishes copying its DNA, completely unaware that its blueprint has been systematically corrupted.
* The Cell-Cycle Trap: The true crisis explodes when the cell hits the G2/M Boundary Checkpoint. This is the cell's strict quality-control gate before it is allowed to enter Mitosis (M phase) and divide. The cell’s internal sensor proteins (like ATR and Chk1) detect that the DNA is heavily corrupted with trifluridine. The cell cycle is slammed into an absolute, structural G2/M arrest. The cell is trapped, unable to move forward into division and unable to slide backward.
## ???? The Leronlimab Intervention: Executing Synthetic Lethality
This hard G2/M checkpoint freeze is exactly where leronlimab executes its synthetic lethality.
When a cell is locked at the G2/M boundary by TAS-102, it is in a state of extreme replication stress. It sends frantic upstream distress signals—principally through the PI3K/AKT/mTOR pathway—to mobilize Homologous Recombination (HR) repair machinery, specifically a master repair protein called RAD51. The cell's entire survival depends on using this AKT signal to patch the trifluridine damage so it can open the G2/M gate.
* Unplugging the Lifeline: The moment leronlimab saturates the CCR5 receptor, it unplugs the G-protein signaling cascade, completely shutting off the downstream PI3K/AKT/mTOR pathway.
* Replication Fork Shattering: With the AKT engine turned off, the cell can no longer stabilize or recruit RAD51 to the damaged DNA. The tumor cell's non-preferred, desperate backup repair pathways (like MMEJ) try to blindly stitch the strands back together, but they cannot handle a hard G2/M arrest under severe starvation conditions.
* Mitotic Catastrophe: The replication forks completely collapse and shatter. The cell cycle cannot hold the line, and the tumor cell is driven directly into mitotic catastrophe and rapid, mass apoptosis.
## ???? The Structural Verdict
This cell-cycle alignment explains why the "mish-mash" of therapies in the earlier basket trial required outlier human biology to achieve long-term complete responses. While FOLFOX and FOLFOXIR damaged DNA, they allowed the tumor cell cycle to drift dynamically through the S phase, leaving open multiple alternative repair pathways that heavily pre-treated KRAS-mutant cells could exploit.
By standardizing the protocol around TAS-102, CLOVER forces every single tumor cell into an identical, inescapable bottleneck at the G2/M checkpoint"
But we still need ici cause pdl1 is going to upreg every time.
Here's the study again
https://www.frontiersin.org/journals/oncology...52022/full
Tas 102 I think is superior here
"
To understand why the CLOVER trial design (TAS-102 + Leronlimab) creates a far more devastating biological trap than the ESMO Basket trial (FOLFOX/FOLFOXIR + Leronlimab), we have to look directly at the sub-cellular level—specifically, how these chemotherapies alter the kinetics of the cell cycle and how leronlimab systematically cuts off their survival routes.
When you change the chemotherapy background, you fundamentally alter the type of cell-cycle crisis you are creating. Here is the deep-dive comparison of how these two environments force the cell cycle into completely different corners.
## ???? The Cell-Cycle Mechanics: How They Break the Engine
To visualize the difference, we must trace how a tumor cell moves through its replication cycle ($G_1 \rightarrow S \rightarrow G_2 \rightarrow M$) and where these drugs slam on the brakes.
[ THE SOLID TUMOR CELL CYCLE REPLICATION LOOP ]
G1 Phase (Growth & Preparation)
│
▼
S Phase (DNA Synthesis / Replication)
├──> FOLFOX / FOLFOXIR: Causes variable breaks & strand adducts.
│ (Cell can try to patch this during active replication)
▼
G2 Phase (Proofreading & Damage Check) ──┐
│ │
▼ ▼
M Phase (Mitosis / Division) [ THE CLOVER CELL-CYCLE TRAP ]
TAS-102 forces a hard G2/M Boundary Arrest.
│
▼
[ LERONLIMAB INTERCEPTION ]
Unplugs AKT/mTOR cascade.
Strips Homologous Recombination (RAD51).
│
▼
REPLICATION FORK SHATTERING
(Immediate Mitotic Catastrophe)
## 1. The ESMO Basket Mix (FOLFOX / FOLFOXIR): Disorganized S-Phase Drifting
The components of FOLFOX and FOLFOXIR target the cell cycle while it is actively copying its blueprint during the S phase (Synthesis):
* The Mechanism: Oxaliplatin creates physical bonds across DNA strands (platinum adducts), while Irinotecan binds to Topoisomerase I, an enzyme that unwinds DNA so it can be read.
* The Cell-Cycle Flaw: These drugs damage the DNA while it is actively replicating. Because the S phase is highly dynamic, the tumor cell doesn't stop immediately. It slows down and activates various complex, alternative DNA-patching mechanisms—like Nucleotide Excision Repair (NER) or Base Excision Repair (BER).
* The Structural Leak: Because the cell-cycle arrest is spread out across the S phase, cells drift through the checkpoint at different velocities. In a heavily pre-treated patient whose cells have already evolved anti-platinum defenses, many cells successfully patch these adducts and slide past the checkpoint into normal division, bypassing the therapeutic effect.
## 2. The CLOVER Design (TAS-102): The Hard G2/M Boundary Wall
The combination protocol standardized in the CLOVER trial drops the S-phase approach entirely and relies on Trifluridine (TAS-102) to execute a synchronized cell-cycle freeze:
* The Mechanism: Trifluridine mimics a standard DNA building block (thymidine). As the cell replicates during the S phase, it mistakenly grabs the trifluridine and stitches it directly into its new DNA strands. The cell finishes copying its DNA, completely unaware that its blueprint has been systematically corrupted.
* The Cell-Cycle Trap: The true crisis explodes when the cell hits the G2/M Boundary Checkpoint. This is the cell's strict quality-control gate before it is allowed to enter Mitosis (M phase) and divide. The cell’s internal sensor proteins (like ATR and Chk1) detect that the DNA is heavily corrupted with trifluridine. The cell cycle is slammed into an absolute, structural G2/M arrest. The cell is trapped, unable to move forward into division and unable to slide backward.
## ???? The Leronlimab Intervention: Executing Synthetic Lethality
This hard G2/M checkpoint freeze is exactly where leronlimab executes its synthetic lethality.
When a cell is locked at the G2/M boundary by TAS-102, it is in a state of extreme replication stress. It sends frantic upstream distress signals—principally through the PI3K/AKT/mTOR pathway—to mobilize Homologous Recombination (HR) repair machinery, specifically a master repair protein called RAD51. The cell's entire survival depends on using this AKT signal to patch the trifluridine damage so it can open the G2/M gate.
* Unplugging the Lifeline: The moment leronlimab saturates the CCR5 receptor, it unplugs the G-protein signaling cascade, completely shutting off the downstream PI3K/AKT/mTOR pathway.
* Replication Fork Shattering: With the AKT engine turned off, the cell can no longer stabilize or recruit RAD51 to the damaged DNA. The tumor cell's non-preferred, desperate backup repair pathways (like MMEJ) try to blindly stitch the strands back together, but they cannot handle a hard G2/M arrest under severe starvation conditions.
* Mitotic Catastrophe: The replication forks completely collapse and shatter. The cell cycle cannot hold the line, and the tumor cell is driven directly into mitotic catastrophe and rapid, mass apoptosis.
## ???? The Structural Verdict
This cell-cycle alignment explains why the "mish-mash" of therapies in the earlier basket trial required outlier human biology to achieve long-term complete responses. While FOLFOX and FOLFOXIR damaged DNA, they allowed the tumor cell cycle to drift dynamically through the S phase, leaving open multiple alternative repair pathways that heavily pre-treated KRAS-mutant cells could exploit.
By standardizing the protocol around TAS-102, CLOVER forces every single tumor cell into an identical, inescapable bottleneck at the G2/M checkpoint"
But we still need ici cause pdl1 is going to upreg every time.
Here's the study again
https://www.frontiersin.org/journals/oncology...52022/full
1
